Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Recruiting · Not applicable · NCT06935591
Conditions: Atrial Fibrillation (AF)
At a glance
- Research payments reported, 2025
- $127,729
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 423
About the trial
- Sponsor
- Vektor Medical (with Veranex Switzerland SA, Veranex)
- Tested
- Pulmonary Vein Isolation (procedure), vMap® + Pulmonary Vein Isolation (device)
- Dates
- Started 2025-06-27; completion 2027-12
- Results posted
- Not yet
The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).
From ClinicalTrials.gov, last updated 2026-03-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Vektor Medical Inc. reported $127,729 in research payments for this study in 2025 (7 payments).
Products named: Vmap
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Matthew S. Mckillop, M.D. Cardiac Electrophysiology · Jacksonville, FL
- Sandeep K. Goyal, MD Cardiac Electrophysiology · Atlanta, GA
- Benjamin D'souza, MD Cardiac Electrophysiology · Cherry Hill, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.